17
Participants
Start Date
August 15, 2023
Primary Completion Date
January 27, 2025
Study Completion Date
January 27, 2025
Imvotamab
Administered intravenously
Omega Research, DeBary, DeBary
Integral Rheumatology & Immunology Specialists, Plantation
Stryde Research, Allen
Precision Comprehensive Clinical Research, Grapevine
Prolato Clinical Research Center, Houston
Care and Cure Clinic, Houston
TriWest Research Associates, San Diego
East Bay Rheumatology, San Leandro
Niepubliczny Zakład Opieki Zdrowotnej Lecznica MAK-MED w Nadarzynie, Nadarzyn
Seoul National University Hospital, Seoul
Lead Sponsor
IGM Biosciences, Inc.
INDUSTRY